Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib

Publisher： Karger

E-ISSN： 1423-0232|88|4|241-246

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.4, 2014-12, pp. : 241-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 167-174

Karger

Access to resources Recommend Favorite

Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 330-341

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 265-272

Karger

Access to resources Recommend Favorite

Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib

By  

Oncology, Vol. 89, Iss. 2, 2015-04 ,pp. : 88-94

Karger

Access to resources Recommend Favorite